Alectinib (INN, marketed as Alecensa) is an oral drug that blocks the activity of anaplastic lymphoma kinase (ALK) and is used to treat non-small-cell lung cancer (NSCLC). It was developed by Chugai Pharmaceutical Co. Japan, which is part of the Hoffmann-La Roche group.

Property Value
dbo:abstract
  • Alectinib (INN, marketed as Alecensa) is an oral drug that blocks the activity of anaplastic lymphoma kinase (ALK) and is used to treat non-small-cell lung cancer (NSCLC). It was developed by Chugai Pharmaceutical Co. Japan, which is part of the Hoffmann-La Roche group. (en)
dbo:alternativeName
  • Alecensa (en)
dbo:bioavailability
  • 37.000000 (xsd:float)
dbo:casNumber
  • 1256580-46-7
dbo:chEBI
  • 90936
dbo:drugbank
  • DB11363
dbo:fdaUniiCode
  • LIJ4CT1Z3Y
dbo:kegg
  • D10542
dbo:pubchem
  • 49806720
dbo:thumbnail
dbo:wikiPageEditLink
dbo:wikiPageExternalLink
dbo:wikiPageExtracted
  • 2019-06-22 02:22:11Z (xsd:date)
dbo:wikiPageHistoryLink
dbo:wikiPageID
  • 48831673 (xsd:integer)
dbo:wikiPageLength
  • 10090 (xsd:integer)
dbo:wikiPageModified
  • 2019-02-18 21:23:38Z (xsd:date)
dbo:wikiPageOutDegree
  • 52 (xsd:integer)
dbo:wikiPageRevisionID
  • 883986951 (xsd:integer)
dbo:wikiPageRevisionLink
dbp:wikiPageUsesTemplate
dct:subject
rdf:type
rdfs:comment
  • Alectinib (INN, marketed as Alecensa) is an oral drug that blocks the activity of anaplastic lymphoma kinase (ALK) and is used to treat non-small-cell lung cancer (NSCLC). It was developed by Chugai Pharmaceutical Co. Japan, which is part of the Hoffmann-La Roche group. (en)
rdfs:label
  • Alectinib (en)
foaf:depiction
foaf:homepage
foaf:isPrimaryTopicOf
owl:sameAs
is foaf:primaryTopic of